Comment on a Word to the Wise About Intranasal Esketamine

Affiliations

Comment

Wayne C Drevets et al. Am J Psychiatry. 2019.

. 2019 Oct 1;176(10):856-857.

doi: 10.1176/appi.ajp.2019.19070688.

¹ Janssen Research and Development, San Diego (Drevets, Singh); Titusville, N.J. (Hough, Daly, Manji); and Beerse, Belgium (Popova).

No abstract available

Keywords: Esketamine; Ketamine; Major Depressive Disorder; Neurology; Neurophysiology; Opioids; S-Ketamine; Treatment-Resistant Depression.

Comment in

More Thoughts on Intranasal Esketamine: Response to Drevets et al.
Schatzberg AF. Schatzberg AF. Am J Psychiatry. 2019 Oct 1;176(10):858-859. doi: 10.1176/appi.ajp.2019.19070688r. Am J Psychiatry. 2019. PMID: 31569985 No abstract available.

A Word to the Wise About Intranasal Esketamine.
Schatzberg AF. Schatzberg AF. Am J Psychiatry. 2019 Jun 1;176(6):422-424. doi: 10.1176/appi.ajp.2019.19040423. Epub 2019 May 21. Am J Psychiatry. 2019. PMID: 31109197 No abstract available.
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Popova V, et al. Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21. Am J Psychiatry. 2019. PMID: 31109201 Clinical Trial.